CoChat

The DOI matches its Crossref record; 193 of the 195 references it cites were found in a registry or an index.

BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment

Cooper, Stephen J, Reynolds, Gavin P, With expert co-authors (in alphabetical order):, Barnes, TRE, England, E, Haddad, PM, Heald, A, Holt, RIG, Lingford-Hughes, A, Osborn, D, McGowan, O, Patel, MX, Paton, C, Reid, P, Shiers, D, Smith, J · 2016 · Journal of Psychopharmacology

Abstract

Excess deaths from cardiovascular disease are a major contributor to the significant reduction in life expectancy experienced by people with schizophrenia. Important risk factors in this are smoking, alcohol misuse, excessive weight gain and diabetes. Weight gain also reinforces service users’ negative views of themselves and is a factor in poor adherence with treatment. Monitoring of relevant physical health risk factors is frequently inadequate, as is provision of interventions to modify these. These guidelines review issues surrounding monitoring of physical health risk factors and make recommendations about an appropriate approach. Overweight and obesity, partly driven by antipsychotic drug treatment, are important factors contributing to the development of diabetes and cardiovascular disease in people with schizophrenia. There have been clinical trials of many interventions for people experiencing weight gain when taking antipsychotic medications but there is a lack of clear consensus regarding which may be appropriate in usual clinical practice. These guidelines review these trials and make recommendations regarding appropriate interventions. Interventions for smoking and alcohol misuse are reviewed, but more briefly as these are similar to those recommended for the general population. The management of impaired fasting glycaemia and impaired glucose tolerance (‘pre-diabetes’), diabetes and other cardiovascular risks, such as dyslipidaemia, are also reviewed with respect to other currently available guidelines. These guidelines were compiled following a consensus meeting of experts involved in various aspects of these problems. They reviewed key areas of evidence and their clinical implications. Wider issues relating to primary care/secondary care interfaces are discussed but cannot be resolved within guidelines such as these.

Overview

Integrity signals

Registry

Crossref · 10.1177/0269881116645254

Cites

193 of 193 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 195 references

Research works printed but not linked: 27

  1. Bennett ME, 2013, Curr Drug Abuse Rev, 13, 180
  2. Das C, 2012, Ann Clin Psychiatry, 24, 225
  3. Hoghton M, 2010, A Step by Step Guide for GP Practices: Annual Health Checks for People with a Learning Disability
  4. Horst WD, 2005, Neuropsychiatric Dis Treat, 1, 349
  5. 10.1176/ps.62.8.pss6208_0882 · doi:10.1176/ps.62.8.pss6208_0882
  6. 10.1192/bjp.183.6.534 · DOI · Paper page
  7. McQuade RD, 2004, J Clin Psychiatry, 65, 47
  8. NICE, 2002, Schizophrenia: Core interventions in the treatment and management of schizophrenia in primary and secondary care
  9. NICE, 2009, Psychosis and schizophrenia: management
  10. NICE, 2011, Alcohol-use disorders: diagnosis, assessment and management of harmful drinking and alcohol dependence
  11. NICE, 2012, Type 2 diabetes: prevention in people at high risk
  12. NICE, 2013, Psychosis and schizophrenia in children and young people: recognition and management
  13. NICE, 2014, Psychosis and schizophrenia in adults: prevention and management
  14. NICE, 2014, Cardiovascular disease: risk assessment and reduction, including lipid modification
  15. NICE, 2014, Obesity: identification, assessment and management
  16. NICE, 2015, Obesity: identification, assessment and management
  17. NICE, 2015, Psychosis and schizophrenia in adults
  18. NICE, 2015, Psychosis and schizophrenia in children and young people
  19. Public Health England, 2016, NHS Health Check: best practice guidance
  20. Puska P, 1998, Bull WHO, 76, 419
  21. Royal College of Psychiatrists, 2010, No health without public mental health: the case for action
  22. Royal College of Psychiatrists, 2012, Report of the National audit of Schizophrenia (NAS) 2012
  23. Royal College of Psychiatrists, 2014, Report of the second round of the National audit of Schizophrenia (NAS) 2014
  24. Schizophrenia Commission, 2012, The abandoned illness: a report from the Schizophrenia Commission
  25. Shiers DE, 2014, Positive Cardiometabolic Health Resource: an intervention framework for patients with psychosis and schizophrenia. 2014 update (with acknowledgement to the late Helen Lester for her contribution to the original 2012 version)
  26. Smith J, 2014, Early Interv Psychiatry, 8, 30
  27. Taylor D, 2012, The Maudsley Prescribing Guidelines in Psychiatry, 11th edn

Cited by

See all 294

Metadata

Authors
Cooper, S. J., Reynolds, G. P., order):, W. E. C.-A. (. A., Barnes, T., England, E., Haddad, P., Heald, A., Holt, R., Lingford-Hughes, A., Osborn, D., McGowan, O., Patel, M., Paton, C., Reid, P., Shiers, D., & Smith, J.
Affiliations
  • Queen's University Belfast (GB)
  • Centre for Mental Health (GB)
  • University of Manchester (GB)
  • Honorary Clinical Professor of Psychiatry, University of Manchester, Manchester, UK
  • Central and North West London NHS Foundation Trust (GB)
  • Hairmyres Hospital (GB)
  • King's College London (GB)
  • Oxleas NHS Foundation Trust (GB)
  • Rethink Mental Illness (GB)
  • Royal College of Psychiatrists (GB)
  • University of Worcester (GB)
Venue
Journal of Psychopharmacology
Published
2016-05-04
Volume
30
Issue
8
Pages
717-748
ISSN
  • 0269-8811 (ISSN-L)
  • 1461-7285
OpenAlex
W2347099014
Cited by
292
References
195
Citations by year
2026: 29 · 2025: 27 · 2024: 38 · 2023: 32 · 2022: 30 · 2021: 50 · 2020: 25 · 2019: 21 · 2018: 22 · 2017: 18
FWCI
18.07
Type
journal article
Language
en
Open access
closed
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Journal of Psychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
  • Worcester Research and Publications (University of Worcester) (acceptedVersion)
  • ePrints Soton (University of Southampton) (acceptedVersion)
  • UCL Discovery (University College London) (submittedVersion)
  • Research Portal (King's College London) (submittedVersion)
  • SHURA (Sheffield Hallam University Research Archive) (Sheffield Hallam University) (submittedVersion)
Funders
National Institute for Health and Care Research (RP-PG-0609-10156, NIHR/CS/009/010)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Social Sciences › Psychology › Clinical Psychology › Eating Disorders and Behaviors
Keywords
antipsychotic-induced weight gain, schizophrenia, cardiovascular risk, diabetes mellitus, impaired fasting glucose, impaired glucose tolerance, dyslipidemia, smoking, alcohol abuse, physical health monitoring, obesity, antipsychotic adverse effects, medication adherence
MeSH terms
Cardiovascular Diseases, Humans, Metabolic Diseases, Obesity, Psychotic Disorders, Risk Factors, Schizophrenia, Antipsychotic Agents, Weight Gain, Overweight

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment. https://app.cochat.ai/papers/10.1177/0269881116645254
The paper
Cooper, S. J., Reynolds, G. P., order):, W. E. C.-A. (. A., Barnes, T., England, E., Haddad, P., Heald, A., Holt, R., Lingford-Hughes, A., Osborn, D., McGowan, O., Patel, M., Paton, C., Reid, P., Shiers, D., & Smith, J. (2016). BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment. Journal of Psychopharmacology. https://doi.org/10.1177/0269881116645254

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.